Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 13, 2005

The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies

  • Ron Maymon , Reuven Sharony , Julia Grinshpun-Cohen , Deganit Itzhaky , Arie Herman and Orit Reish


Aims: To evaluate the cross-trimester multiple marker correlation and the minimum marker combination needed for detecting various chromosomal aneuploidies.

Materials and methods: Parturient women with singleton pregnancies who underwent non-interventional sequential screening test and followed prospectively were recruited. They all underwent first trimester combined nuchal translucency (NT), pregnancy-associated plasma protein-A (PAPP-A), and free β-human chorionic gonadotrophin (f-βhCG), followed by second trimester measurement of unconjugated estriol (uE3), human chorionic gonadotrophin (hCG) and alpha-fetoprotein (AFP). Pearson correlation was applied to compute any cross-trimester marker correlation and logistic regression analysis was used to determine the minimum marker combination for detecting various categories of chromosomal aneuploidies.

Results: The current study included 552 normal and 43 chromosomal-affected pregnancies (24 Down's syndrome [DS], 7 Turner's syndrome, 8 Edward's syndrome, 4 Klinefelter syndrome and 5 triploidy) for which the results of both the screening tests and the pregnancy outcome were available. In the normal cases, a significant correlation was found between f-βhCG and hCG (r=0.52), as well as between PAPP-A and uE3 (r=0.174). In DS pregnancies, the NT correlated with both hCG (r=0.45) and uE3 (r=−0.39). In Turner's syndrome, uE3 correlated both with PAPP-A (r=0.97) and f-βhCG (r=0.97). No other significant correlations were found. Furthermore, with the exception of f-βhCG and hCG in the unaffected cases, all other markers correlation appeared very weak. For detecting all the above categories of aneuploidies, the combination of NT, PAPP-A and uE3 and the maternal age background risk were found adequate, with a 74% detection rate (DR) for a 5% false positive rate (FPR). For DS only, the combination of maternal age-related background risk and the combination of NT, PAPP-A, hCG and AFP yielded a 79% DR for a 5% FPR.

Conclusions: The current study agrees with a previous report that, overall, there is no strong correlation between first and second trimester markers. The extension of the integrated test for detecting various categories of common chromosomal aneuploidies using NT, PAPP-A and uE3 deserves further evaluation.


Corresponding author: Ron Maymon, MD Department of Obstetrics and Gynecology Assaf Harofe Medical Center Zerifin Israel Tel.: +972-3-6407445 Fax: +972-3-6409043


1 Benn PA, A Gainey, CJ Ingardia, JF Rodis, JF Egan: Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn21 (2001) 680Search in Google Scholar

2 Benn PA, J Ying, T Beazoglou, JF Egan: Estimates for the sensitivity and false-positive rates for second trimester screening for Down syndrome and trisomy 18 with adjustment cross-identification and double-positive results. Prenat Diagn21 (2001) 46Search in Google Scholar

3 Bowes WA Jr: Editorial. Obstet Gynecol Surv55 (2000) 10Search in Google Scholar

4 Campogrande M, E Viora, G Errante, S Bastonero, A Sciarrone, P Grassi Pirrone, M Perona, G Mancini, D Dall'Amico, E Pavanello, V Guaraldo: Correlations between first and second trimester markers for Down's syndrome screening. J Med Screen8 (2001) 163Search in Google Scholar

5 Canini S, F Prefumo, L Famularo, PL Venturini, V Palazzese, P De Biasio: Comparison of first trimester, second trimester and integrated Down's syndrome screening results in unaffected pregnancies. Clin Chem Lab Med40 (2002) 600Search in Google Scholar

6 Copel JA, RO Bahado-Singh: Editorial. Performing screening for Down's syndrome – a search for the family's values. N Engl J Med341 (1999) 521Search in Google Scholar

7 De Biasio P, S Canini, Prefumo, L Famularo, PL Venturini: Extent of correlation between first and second trimester markers for Down's syndrome screening. J Med Screen7 (2000) 163Search in Google Scholar

8 Ferguson-Smith MA: Which prenatal screening protocol? Prenat Diagn24 (2004) 76110.1002/pd.1038Search in Google Scholar PubMed

9 Gilbert RE, C Augood, R Gupta, AE Ades, S Logan, M Sculpher, JHP van der Meulen: Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ323 (2001) 423Search in Google Scholar

10 Greene NH, LD Platt, R Wapner: Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol105 (2005) 439Search in Google Scholar

11 Halperin R, A Zimmerman, R Langer, I Bukovsky, D Schneider: Laminaria dilatation and evacuation for pregnancies with mid-trimester premature rupture of membranes: a retrospective cohort study. Eur J Obstet Gynecol Reprod Biol100 (2002) 181Search in Google Scholar

12 Halperin R, Z Vaknin, I Ben-Ami, I Bukovsky, D Schneider: Termination of multiple pregnancy at 18–24 weeks' gestation by laminaria dilatation and evacuation. J Reprod Med49 (2004) 357Search in Google Scholar

13 Herman A, E Dreazen, J Tovbin, O Reish, I Bukovsky, R Maymon: Correlation and overlapping between nuchal translucency and triple among Down syndrome-affected pregnancies. Fetal Diagn Ther18 (2002) 196Search in Google Scholar

14 Herman A, E Dreazen, J Tovbin, Z Weinraub, I Bukovsky, R Maymon: Comparison between disclosure and non-disclosure approaches for trisomy 21 screening tests. Hum Reprod17 (2002) 1358Search in Google Scholar

15 Huang T, E Alberman, N Wald, AM Summers: Triploidy identified through second-trimester serum screening. Prenat Diagn25 (2005) 229Search in Google Scholar

16 Malone FD: Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol105 (2005) 43810.1097/01.AOG.0000153257.08966.f9Search in Google Scholar PubMed

17 Maymon R, A Shulman: Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. Hum Reprod11 (2001) 691Search in Google Scholar

18 Maymon R, M Bergman, S Segal, E Dreazen, Z Weinraub, A Herman: Sequential first and second trimester screening tests: correlation of the markers' levels in normal versus Down's syndrome affected pregnancies. Prenat Diagn21 (2001) 1175Search in Google Scholar

19 Maymon R, M Betser, E Dreazen, A Padoa, A Herman: A model for disclosing the first trimester part of an integrated Down's syndrome screening test. Clin Genet65 (2004) 113Search in Google Scholar

20 Maymon R, A Herman: The clinical evaluation and pregnancy outcome of euploid fetuses with increased nuchal translucency. Clin Genet66 (2004) 426Search in Google Scholar

21 Muller F, C Sault, C Lemay, N Roussel-Mizon, F Forestier, J-L Frendo: Second trimester two-step trisomy 18 screening using maternal serum markers. Prenat Diagn22 (2002) 605Search in Google Scholar

22 Nicolaides KH: Screening for chromosomal defects. Ultrasound Obstet Gynecol21 (2003) 31310.1002/uog.128Search in Google Scholar PubMed

23 Palomaki GE, LM Neveux, GJ Knight, JE Haddow: Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn24 (2003) 243Search in Google Scholar

24 Pandya PP, RJM Snijders, SJ Johnson, MJ de Lourdes Brizot, KH Nicolaides: Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10–14 weeks of gestation. Br J Obstet Gynaecol102 (1995) 957Search in Google Scholar

25 Platt LD, N Greene, A Johnson, J Zachary, E Thom, D Krantz: Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol104 (2004) 661Search in Google Scholar

26 Schneider D, R Halperin, R Langer, E Caspi, I Bukovsky: Abortion at 18–22 weeks by laminaria dilatation and evacuation. Obstet Gynecol88 (1996) 412Search in Google Scholar

27 Spencer K, AW Liao, H Skentou, S Cicero, KH Nicolaides: Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn20 (2000) 495Search in Google Scholar

28 Spencer K, C Ong, H Skentou, AW Liao, KH Nicolaides: Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn20 (2000) 411Search in Google Scholar

29 Spencer K, N Tul, KH Nicolaides: Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn20 (2000) 390Search in Google Scholar

30 Tul N, K Spencer, P Noble, C Chan, KH Nicolaides: Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn19 (1999) 1035Search in Google Scholar

31 Wald N, A Rodeck, A Hackshaw, J Walters, L Chitty, A Mackinson: First and second trimester antenatal screening for Down's syndrome. The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen10 (2003) 56Search in Google Scholar

32 Wald NJ, HC Watt, AK Hackshaw: Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med341 (1999) 461Search in Google Scholar

33 Wright D, I Bradbury, P Benn, H Cuckle, K Ritchie: Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn24 (2004) 762Search in Google Scholar

Published Online: 2005-09-13
Published in Print: 2005-10-01

©2005 by Walter de Gruyter Berlin New York

Downloaded on 25.2.2024 from
Scroll to top button